Inclusion Criteria:

          -  Diagnosis of an advanced local or metastatic solid tumor

          -  Adequate hematologic, hepatic, renal, and coagulation function

          -  Tumor is the type where published clinical data would suggest that anthracyclines have
             cytotoxic activity

        Exclusion Criteria:

          -  Prior exposure to 300 mg/m^2 of Dox HCl or DOXIL / CAELYX ® or 600 mg/m^2 of
             Epirubicin HCl

          -  CHF, severe myocardial insufficiency, or cardiac arrhythmia

          -  Any of the following within 28 days prior to Cycle 1 Day 1:

               -  Major surgery, as defined by the Investigator

               -  Radiotherapy

               -  Chemotherapy, immunotherapy and/or anticancer therapy (except for small molecule
                  kinase inhibitors, which are 6 elimination half-lives)

               -  Currently enrolled in or discontinued from a clinical study involving an
                  investigational agent or non-approved use of a drug or device, or concurrently
                  enrolled in any other type of medical research judged not to be scientifically or
                  medically compatible with this study